| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Glymidine sodium targets pancreatic β-cells to stimulate insulin secretion. It functions as an inhibitor of hepatic lipolysis. The compound inhibits glucose formation and suppresses elevated pyruvate oxidation resulting from inhibition of endogenous lipid mobilization. It also increases the sensitivity of peripheral tissues to insulin.
|
|---|---|
| ln Vitro |
In vitro, glymidine sodium inhibits glucose formation and suppresses elevated pyruvate oxidation that results from inhibition of endogenous lipid mobilization. It stimulates insulin secretion from pancreatic β-cells. The compound's mechanism involves inhibition of hepatic lipolysis and modulation of glucose metabolism.
|
| ln Vivo |
In vivo, glymidine sodium is an orally active antidiabetic agent that lowers blood glucose levels. It exhibits a relatively long duration of action. The compound is used with diet to manage blood glucose in diabetic patients. Risks of hypoglycemia may be associated with its use, particularly in elderly or renally impaired patients.
|
| Enzyme Assay |
Insulin secretion assays are performed using isolated pancreatic islets or β-cell lines (e.g., MIN6 or INS-1 cells). Cells are treated with glymidine sodium at various concentrations (typically 1-100 µM) in glucose-containing buffer. Insulin released into the culture medium is measured by ELISA or radioimmunoassay. Glucose uptake assays in peripheral tissues or adipocytes assess insulin sensitizing effects.
|
| Cell Assay |
Pancreatic β-cell lines (e.g., MIN6 or INS-1) are cultured in appropriate media at 37°C with 5% CO₂. Cells are pre-incubated in low-glucose buffer and then stimulated with glymidine sodium at various concentrations in the presence of glucose. After incubation, supernatant is collected and insulin concentration is measured by ELISA. For hepatic lipolysis studies, primary hepatocytes are treated with the compound and free fatty acid release is measured.
|
| Animal Protocol |
Animal studies are conducted in diabetic rodent models (e.g., streptozotocin-induced diabetic rats or db/db mice). Glymidine sodium is administered orally by gavage at specified doses. Blood glucose levels are measured at various time points post-administration. Oral glucose tolerance tests (OGTT) are performed to assess glucose-lowering efficacy. Insulin levels and lipid profiles are measured in serum samples.
|
| ADME/Pharmacokinetics |
Glymidine sodium has molecular formula C₁₃H₁₄N₃NaO₄S and molecular weight 331.32. It is soluble in DMSO (~125 mg/mL, ~377.28 mM). The compound has a melting point of 221-226°C, boiling point of 515.1°C at 760 mmHg, and LogP of 2.242. It is a sulfonamide hypoglycemic agent.
|
| References | |
| Additional Infomation |
Glymidine sodium (trade name Gondafon) is a sulfapyrimidine derivative with antihyperglycemic/antidiabetic activity. It is used with diet to lower blood glucose by increasing insulin secretion and peripheral insulin sensitivity. The compound exhibits a relatively long duration of action and has been studied for its potential risks of hypoglycemia, particularly in elderly or renally impaired patients. It also functions as an inhibitor of hepatic lipolysis.
|
| Molecular Formula |
C13H14N3O4S-.NA+
|
|---|---|
| Molecular Weight |
331.32276
|
| Exact Mass |
331.06
|
| Elemental Analysis |
C, 47.13; H, 4.26; N, 12.68; Na, 6.94; O, 19.32; S, 9.68
|
| CAS # |
3459-20-9
|
| Related CAS # |
339-44-6 (free acid);3459-20-9 (sodium);
|
| PubChem CID |
23691021
|
| Appearance |
Solid powder
|
| Density |
1.354g/cm3
|
| Boiling Point |
515.1ºC at 760mmHg
|
| Melting Point |
221-226°
|
| Flash Point |
265.4ºC
|
| LogP |
2.242
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
399
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].COCCOC1C=NC([N-]S(C2C=CC=CC=2)(=O)=O)=NC=1
|
| InChi Key |
HCLFWAHLVGHDOL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H14N3O4S.Na/c1-19-8-9-20-11-4-2-5-12(10-11)21(17,18)16-13-14-6-3-7-15-13;/h2-7,10H,8-9H2,1H3;/q-1;+1
|
| Chemical Name |
sodium;[3-(2-methoxyethoxy)phenyl]sulfonyl-pyrimidin-2-ylazanide
|
| Synonyms |
BS 717; Glycanol; Glycodiazin; Glycodiazine; Glycodiazine sodium; Glyconormal; Glymidine; Glymidine sodium; Glymidine sodium salt; Gondafon; Lycanol; Redul; Redul IF; Redul sodium; SH 717;
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~377.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0182 mL | 15.0912 mL | 30.1823 mL | |
| 5 mM | 0.6036 mL | 3.0182 mL | 6.0365 mL | |
| 10 mM | 0.3018 mL | 1.5091 mL | 3.0182 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
